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Abstract
Introduction—[11C](R)-Rolipram is a selective radioligand for PET (positron emission
tomography) imaging of phosphodiesterase 4, an enzyme that metabolizes cAMP. The aim of this
study was to estimate the human radiation absorbed dose of the radioligand based on its
biodistribution in both monkeys and humans.
Methods—Whole-body PET images were acquired for 2 h after injecting [11C](R)-rolipram in eight
healthy humans and three monkeys. The simple method of using a single 2-dimensional (2D) planar
image was compared to more time consuming methods that used two (bisected) or four (quadrasected)
tomographic images in the anteroposterior direction.
Results—Effective dose was 4.8 µGy/MBq based on 2D planar images. The effective dose was
only slightly lower by 1% and 5% using the bisected and quadrasected images, respectively.
Nevertheless, the two tomographic methods may have more accurately estimated the exposure of
some organs (e.g., kidneys) that are asymmetrically located in the body or have radioactivity that
appears to overlap on 2D planar images. Monkeys had a different biodistribution pattern compared
to humans (e.g., greater urinary excretion) such that their data overestimated the effective dose in
humans by 40%.
Conclusions—The effective dose of [11C](R)-rolipram was modest and comparable to that of
other 11C-labeled radioligands. The simple, and far less time consuming, 2D planar method provided
accurate and somewhat more conservative estimates of effective dose than the two tomographic
methods. Although monkeys are commonly used to estimate human radiation exposures, their data
gave a considerable overestimation for this radioligand.
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INTRODUCTION
The second messenger cAMP (3’, 5’-cyclic adenosine monophosphate) acts in the signal
transduction of several neurotransmitters and may play an important role in psychiatric
illnesses, including mood disorders [1] and drug addiction [2]. For example, the mechanism
of action of several antidepressant treatments, including medications and electroconvulsive
therapy, is thought to include upregulation of cAMP and its signal cascade [1,3–5]. Of at least
11 known families of mammalian cyclic nucleotide phosphodiesterases, phosphodiesterase 4
(PDE4) specifically metabolizes cAMP and is highly expressed in brain [6,7]. Inhibition of
PDE4 would increase intracellular cAMP signaling, just like the putative mechanism of
antidepressant medications. Rolipram is an inhibitor of PDE4 and, in fact, does have
antidepressant effects in both animals [8,9] and humans [10]. Rolipram was, however,
discontinued in clinical trials because of emetic and sedative side effects.
The more active isomer (R) of rolipram has been labeled with 11C and successfully used for
positron emission tomography (PET) imaging in rodents [11,12], monkeys [13], and humans
[14]. The radioligand has high brain uptake and low levels of nonspecific binding [15] and is
a promising agent to image and to measure PDE4 in brain. The biodistribution and estimated
radiation doses of [11C](R)-rolipram in humans has not been reported. The radiation dosimetry
profile of the radioligand was partially estimated in rats [12]; however, no effective dose was
estimated and only selected organ doses were listed in that report. Thus, the first aim of the
present study was to determine the biokinetics and radiation safety of the radioligand through
whole-body PET imaging in humans. The second aim was to compare the estimated radiation
doses from 2-dimensional (2D) planar, bisected, and quadrasected images for [11C](R)-
rolipram. As described in previous work of our laboratory, PET images obtained in this type
of whole-body dosimetry study can be reinterpolated and reformatted to vary the thickness of
each slice for analysis in any plane [16]. In this prior work, analysis of 2D planar or bisected
images was found to estimate radiation doses more conservatively than thin-slice images for
a radioligand that had a fairly broad biodistribution in the body. In addition, the report
demonstrated that analysis of compressed 2D planar images resulted in a considerable savings
in time in comparison to minimally compressed thin-slice images without compromising the
estimated radiation doses. Finally, the third aim was to determine whether results from whole-
body imaging of monkeys could provide accurate estimates of radiation exposure to humans.
MATERIALS AND METHODS
Radiopharmaceutical Preparation
[11C](R)-Rolipram was synthesized by 11C-methylation of (R)-desmethyl-rolipram using the
route and method previously described by Fujita et al. [15]. Additional details are available
from our Investigational New Drug application posted at: http://kidb.bioc.cwru.edu/snidd/. For
the present study, the radiochemical purity of all syntheses for both humans and monkeys (n
= 10) was >99%, with average specific activities at the time of injection of 112.3 ± 28.2 GBq/
µmol. These and subsequent data are expressed as the mean ± SD.
Human Subjects
The use of [11C](R)-rolipram in human subjects for this study was approved by the U.S. Food
and Drug Administration, the Radiation Safety Committee of the National Institutes of Health,
and the Institutional Review Board of the National Institute of Mental Health. Eight healthy
volunteers to meet selection criteria were enrolled in the study: four male and four female
subjects (mean age, 41 ± 9 y; age range, 25–51 y; weight, 89 ± 20 kg). Subjects provided
informed, written consent before completing a screening assessment consisting of a history,
physical examination, electrocardiogram, and standard blood and urine analyses, including
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drug screening. Following the completion of his or her PET scan, each subject repeated the
complete blood count, serum chemistries, and urinalysis.
Human PET Imaging
Subjects underwent both transmission and dynamic emission scans on a GE Advance
tomograph (GE Healthcare, Waukesha, WI). Following injection of 709 ± 79 MBq of 11C]
(R)-rolipram, each subject was imaged in 7 contiguous 15-cm bed positions beginning at the
head and continuing to the middle of the thigh, following the protocol described by Sprague
et al. [16].
Each subject’s original tomographic PET images (256 × 256 pixels on transaxial planes) were
compressed in the anteroposterior direction by summing up all activities along this direction
to create three whole-body image sets: 2D planar, bisected, and quadrasected.
a. 2D planar Images. All 256 tomographic images were compressed to construct a single
planar image (Fig 1).
b. Bisected Images. The 256 tomographic images were split into two sets of 128 and
then compressed. In effect, this divided the body through the mid-coronal plane to
create anterior and posterior planar image slices.
c. Quadrasected Images. The 256 tomographic images were examined in a sagittal view
to determine the anterior and posterior limits of each subject’s body within the field
of view. Four sets of 40–45 contiguous tomographic slices encompassing the entire
body were compressed to create four planar image slices that effectively quadrasected
the body.
Analysis of all three image types was performed using PMOD 2.8 (pixelwise modeling
computer software; PMOD Group, Adliswil, Switzerland). Source organs were those that could
be visually identified on all three types of images: brain, heart, lungs, liver, gallbladder, left
kidney, and urinary bladder. Regions of interest were drawn around each on the 2D planar
images. In the case of the bisected and quadrasected image analyses, regions of interest were
drawn around each of these structures on all of the slices in which they appeared. Uptake of
activity in the heart was uniform and diffuse rather than confined solely to the myocardium.
Therefore, all activity contained within the heart was designated as heart contents, not heart
wall. The right kidney was not clearly distinguished, since its borders frequently overlapped
liver and gallbladder. In addition, both kidneys were often difficult to identify on the 2D planar
images due to diffuse overlapping activity in the abdominal cavity. Thus, the left kidney was
identified on the posterior bisected images and applied to the 2D planar images. Total uptake
of activity in the kidneys was calculated as twice that of the left kidney for all three image
types.
Animal PET Imaging
Three male rhesus monkeys (12.6 ± 2.4 kg) were scanned following injection of 282 ± 110
MBq [11C](R)-rolipram. To allow intubation before scanning, each monkey was anesthetized
with ketamine 10 – 15 mg/kg IM, propofol 1.2 – 4 mg/kg IV, and glycopyrrolate 0.15 – 0.2
mg/kg IV. To minimize the potential effects of ketamine on PDE4 imaging, the scans started
at least 90 min after its administration.
All three whole-body scans were performed on a GE Advance tomograph. The first two
monkeys were scanned in four contiguous 15-cm bed positions from the top of the head to the
mid-thigh. Emission scans consisted of 22 whole-body dynamic scans, and the scanning time
for each bed position within a given dynamic scan increased as follows: 4 × 0.25, 4 × 0.5, 8 ×
1, 4 × 2, and 2 × 4 min. The third monkey was scanned in five contiguous 15-cm bed positions
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for a total of 18 dynamic scans. Individual bed positions within the dynamic scans were imaged
as follows: 2 × 0.25, 3 × 0.5, 6 × 1, 5 × 2, 2 × 4 min. The total scanning time for both methods
was about 120 min.
The 256 tomographic PET images were compressed coronally in the anteroposterior direction
to create a single 2D planar image for each subject as previously described. Analysis of the
images was again performed with PMOD 2.8, and regions of interest were drawn around
visually identifiable source organs: brain, heart, lungs, liver, left kidney, right kidney, and
urinary bladder. As in human subjects, activity confined within the heart was assigned to the
heart contents. Because both kidneys were visualized in animal subjects, total uptake of activity
was calculated as the sum of the left and right kidneys.
Residence Time Calculations
For each of the three methods of analysis, the uptake of activity for source organs was corrected
for overall recovery of injected activity by comparing the amount of activity contained in a
large region placed over the entire body to the injected activity at each time point. The activity
in each source organ was multiplied by 100/x, where “x” is the calculated percent recovery at
each time point. These adjustments ensured that the uptake of activity in source organs was
not underestimated. The recovery of activity averaged 88% across all time points in humans
and 87% in monkeys.
Decayed activity from each source organ, including the urinary bladder, was converted to a
percentage of injected activity and plotted versus time. Before creating these curves,
adjustments were made to the acquisition time points for organs that were not confined to a
single 15-cm bed position. Accurate mean acquisition times for these organs were obtained by
weighting the time points associated with each bed position in which the organ appeared
relative to the fraction of the organ’s activity in each frame.
The area under an organ’s decayed activity curve from time zero to infinity is equal to residence
time. The trapezoidal rule was used to calculate the area under the curve from the time of
injection to the time image acquisition terminated. Any further decline in activity was assumed
to occur by physical decay without any biological clearance. Please note, however, that the
figures displayed herein (Fig. 2 and Fig. 4) illustrate decay-corrected activity for individual
organs, since this format is more typical for PET time-activity curves. Because the cumulative
urinary bladder activity could not be fitted with a suitable bi-exponential curve for use in a
voiding bladder model, urinary bladder residence times were calculated in the same fashion as
were other source organs. Residence times of all individual source organs were summed and
subtracted from the fixed theoretical value of T1/2 / ln 2 = 0.4906 h to calculate the residence
time of the “remainder of body” for each subject. Radiation doses were determined for each
subject by entering the residence times calculated into OLINDA/EXM 1.0 (Organ Level
Internal Dose Assessment/Exponential Modeling computer software; Vanderbilt University,
2003) [17] and were based on the MIRD scheme of a 70-kg adult male [18].
For monkey subjects, residence times were calculated as described above but converted into
corresponding human values by multiplication with the following factor designed to scale
organ and body weights: (oh / bh)/(om / bm), where oh and om are the organ weights of human
and monkey, respectively, and bh and bm are the body weights of human and monkey,
respectively. The adjusted residence times were entered into OLINDA/EXM 1.0, and the
radiation doses were again based on the model of a 70-kg human adult male.
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RESULTS
Human Biodistribution
Intravenous injection of [11C](R)-rolipram produced no clinically observable effects. Blood
pressure, pulse, respiratory rate, and ECG readings did not show any significant change from
baseline measurements. In addition, blood and urine tests performed about 2.5 h after the
administration of the tracer showed no significant changes from the results obtained at the
subject's initial assessment.
After injection of [11C](R)-rolipram, the brain, gallbladder, heart, kidneys, liver, lungs, and
urinary bladder were visually identified as source organs on 2D planar (Fig. 1), bisected, and
quadrasected image sets. The liver had the highest uptake of activity with a peak of 21% of
injected activity (n = 8) on the 2D planar dataset about 1 min after injection. Peak values of
radioactive uptake measured for the heart, lungs, and brain were 7.6%, 6.9%, and 4.0% injected
activity, respectively, all occurring within 15 min of injection (Figs. 2 A and B). The uptake
of activity in the kidneys and gallbladder did not reach an apex during the course of the emission
scans, suggesting that both hepatobiliary and renal clearance were still increasing 2 h after the
administration of the tracer. The upward parabolic trend of the time-activity curve for the
urinary bladder (Fig. 2 A) also indicated that urinary clearance was continuing at the end of
scanning. As a result, the urinary bladder uptake could not be fitted with a mono- or bi-
exponential curve, and a dynamic bladder model was not used to calculate the urinary bladder
residence time.
Among the three methods of analysis, the largest differences in residence times occurred
between the 2D planar and quadrasected methods (Table 1). The 2D planar residence times
were higher than the quadrasected data for each of the source organs. This difference was
magnified in those organs that are asymmetrically localized in either the anterior or posterior
aspect of the body (i.e., the heart, kidneys, gallbladder, and urinary bladder). With the exception
of the lungs, the bisected images provided residence times for source organs that were
intermediate to the values obtained from the 2D planar and quadrasected images. The residence
time of the lungs was unexpectedly higher in the bisected analysis than that in the planar method
by a factor of 1.03. This aberration is most likely insignificant and probably occurred due to
the difficulty in defining the border between heart and lungs on the 2D planar images. A small
amount of activity that was assigned to the lungs on bisected images may have been incorrectly
assigned to the heart on the 2D planar images. As expected, the “remainder of body” residence
time was lowest for the 2D planar analysis and highest for the quadrasected method, due to the
remainder’s inverse correlation with the amount of activity in source organs.
For the three methods of analysis, differences in doses to individual organs reflected the
differences in their residence times. In comparison to the 2D planar method, the doses for
individual organs varied by factors of 0.65–1.06 and 0.6–1.1 for the bisected and quadrasected
methods, respectively (Table 2). The organs with the highest radiation doses (µGy/MBq) in
the 2D planar image analysis were the gallbladder wall (23), kidneys (20), urinary bladder wall
(19), and liver (15). The above organs had the highest doses in the bisected and quadrasected
image analyses as well. The effective dose obtained from the 2D planar analysis was 4.8 µGy/
MBq. The greatest difference among doses occurred when comparing the 2D planar and
quadrasected values of asymmetrically localized organs. Doses for these and all other source
organs were always higher in the 2D planar than in the quadrasected analysis. In contrast,
organs that were not designated as source organs often showed slightly higher doses in the
bisected and quadrasected analyses than in the 2D planar method. These differences were due
to the fact that more activity was assigned to the “remainder of body” in the bisected and
quadrasected analyses. The effective dose was 1% and 5% lower for the bisected and
quadrasected methods, respectively, compared to the 2D planar analysis,
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Monkey Biodistribution
Intravenous injection of [11C](R)-rolipram produced no significant changes in pulse,
respiratory rate, or ECG readings. The brain, heart, kidneys, liver, lungs, and urinary bladder
were all visually identified as source organs on 2D planar images (Fig. 3). Among the organs
whose uptake of activity peaked during the course of the emission scans, the liver showed the
highest uptake with a peak of 24% injected activity about 3 min after the injection of [11C]
(R)-rolipram. Average peak uptake in the lungs, kidneys, brain, and heart was 7.8%, 7.3%,
7.2%, and 3.4% injected activity, respectively, all occurring within 10 min of injection (Fig. 4
A and B). Although the urinary bladder time-activity curve showed a slight curvature (Fig. 4
A), fitting did not converge with either a mono- or bi-exponential function. Thus, a voiding
bladder model was not used to calculate the urinary bladder residence time.
Mean residence times were calculated based on the imaging data acquired from three different
monkeys by using the weighting factor described in Materials and Methods to convert to human
values (Table 1). Based on these residence times, the organs with the highest radiation doses
(µGy/MBq) were the urinary bladder wall (57), kidneys (26), liver (12), and lungs (11). The
estimated human effective dose from the monkey 2D planar analysis was 6.6 µGy/MBq, which
was 40% higher than that estimated from human images (4.8 µGy/MBq).
Percent Recovery of Injected Activity
The recovery of injected activity declined during the scanning of both humans and monkeys.
From the beginning to the end of scans in every monkey and in the average of all 8 human
subjects, the recovery of activity declined by about 4%. Average recovery in both humans and
monkeys declined from about 90% to 86%. This loss of radioactivity could have been caused
by distribution within the body but outside the field of view (i.e., below the mid-thigh) or
possibly by exhaling radioactivity. Krause et al. demonstrated that the O-methyl group in
rolipram is cleaved during metabolism in humans and in cynomolgus monkeys, though not in
rhesus monkeys [19]. We prepared [11C](R)-rolipram with 11C in this methoxy position (Fig.
5). After cleavage, the radioactive species containing radioactive carbon would likely be
rapidly metabolized and exhaled as [11C]CO2 [20]. Thus, the decreased recovery of
radioactivity in humans, but not necessarily rhesus monkeys, could reflect the often overlooked
route of pulmonary excretion.
Comparison of Monkey and Human Biodistribution Data
The uptake and biodistribution of activity following injection of [11C](R)-rolipram were
somewhat similar in monkeys and humans. With the exception of the gallbladder, which was
only visible in human subjects, the same source organs were identified in both groups. The
overall human effective dose calculated from the monkey data was 1.4-fold higher than that
calculated from the human 2D planar images (Table 2). The greatest differences were seen in
the kidneys and brain, which were overestimated in monkeys by factors of 2.9 and 1.6,
respectively, while the heart wall and gallbladder were underestimated by factors of 0.39 and
0.15, respectively.
DISCUSSION
The present study reports the biodistribution and radiation doses of the PDE4 imaging agent
[11C](R)-rolipram. Human whole-body PET analyzed with 2D planar images estimated a
modest effective dose of 4.8 µGy/MBq. The low mass dose of carrier rolipram (1.73 ± 0.46
µg) injected with [11C](R)-rolipram produced no subjective effects and no meaningful changes
in laboratory tests, EKG, blood pressure, pulse, and respiration rate. Therefore, [11C](R)-
rolipram appears safe from both pharmacologic and radiation exposure standpoints.
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Uptake of radioactivity was highest in liver for human subjects with a peak value of 21%
injected activity about 1 min after injection of [11C](R)-rolipram. Despite this initial uptake of
radioligand, liver activity decreased by about 40% within 30 min, and the estimated radiation
dose (µGy/MBq) to liver (15) was actually lower than gallbladder wall (23), kidneys (20) and
urinary bladder wall (19). Collectively, these doses suggest high levels of excretion occurred
via both hepatobiliary and urinary routes. Excretion of radioactivity via the urine was
substantial. Urinary bladder uptake (41% injected activity in monkeys and 16% injected
activity in humans) was continuing to increase at the end of the scans. However, with only two
hours of data, an estimate of total excretion via urine cannot be made. At two hours, activity
in the urinary bladder of monkeys was just beginning to plateau, whereas that of human was
still linearly increasing.
Comparison with Pharmacokinetic Data
The pharmacokinetics of rolipram have been relatively thoroughly studied in animals and
humans as part of its evaluation as an antidepressant medication [19,21–23]. Nevertheless,
only limited analogies are possible between these pharmacokinetic data and the current
biodistribution study, because different portions of the molecule are monitored and because
different lengths of observation are used. Pharmacokinetic studies of rolipram monitored the
parent compound itself or monitored radioactivity from tritium in [3H]rolipram, labeled at
position 5 of the phenyl ring [19] (Fig. 5). In contrast, we measured radioactivity from 11C on
the O-methyl group (Fig. 5). The prior clinical pharmacology studies in humans, rodents, and
monkeys identified eight major metabolites formed mainly through hydroxylation or cleavage
of either ether function [19,22]. In all species, rolipram was almost completely metabolized
within 24 h, and more than 80% of both orally and intravenously administered 3H radioactivity
was excreted via urine [19,22]. We also found that a sizeable percentage of 11C radioactivity
from intravenously administered [11C](R)-rolipram was excreted via urine: at least 41% in
monkeys and 16% in humans by 2 h. Nevertheless, we cannot estimate the amount of 11C that
would be excreted in 24 h and could probably not accurately measure the small amount of
activity remaining at that late time. Comparisons are made even more difficult to interpret as
the relative abundance of different metabolites in urine were not noted in the pharmacokinetic
analysis, and we did not perform metabolite analyses in the present study. Thus, although
pharmacokinetic evaluations of rolipram and the present whole-body imaging study of [11C]
(R)-rolipram provide partially overlapping data, neither method could completely substitute
for the other.
Comparison of 2D Planar, Bisected, and Quadrasected Methods
2D planar images slightly overestimated radiation doses to individual source organs in
comparison to bisected and quadrasected images. Differences in organ doses were greatest
between 2D planar and quadrasected analyses for asymmetrically located organs (i.e., heart,
kidneys, gallbladder, and urinary bladder). The largest discrepancy among the methods was
the dose to the gallbladder (23 µGy/MBq), which was 40% higher for the 2D planar analysis
than the quadrasected method. Similar differences among methods of analysis were seen in
our laboratory’s prior report on a neurokinin type 1 receptor antagonist [18F]SPA-RQ [16]. As
noted in that report, the medical significance of the overestimation of individual organ doses
is questionable, as the higher values obtained from 2D planar analysis represent more
conservative estimates of radiation risk.
Despite differences in organ doses, the overall effective dose, which is commonly viewed as
the primary measure of radiation risk, was quite similar for all three analyses. The effective
dose (µGy/MBq) estimated from 2D planar images (4.8) was about 1% higher than the bisected
estimate (4.7) and 5% higher than the quadrasected estimate (4.5). These small differences are
similar to those seen in our previous report on [18F]SPA-RQ [16], where 2D planar effective
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dose estimates were 10% higher than minimally compressed thin-slice images. Therefore, the
higher, more conservative 2D planar doses are again reasonable estimates of radiation
exposure.
In certain cases, a combination of 2D planar, bisected, and quadrasected analyses may be most
appropriate. As noted previously, the borders of kidneys were often difficult to identify on 2D
planar images in the present study. Kidneys were instead identified on posterior bisected
images, and more accurately drawn regions were then propagated to the corresponding 2D
planar image. This strategy does not appear to have been of great significance in the present
study, as the estimated 2D planar dose to the kidney was only 4% and 9% higher than the
bisected and quadrasected values, respectively. Nevertheless, a combination of methods may
be indicated for a radioligand highly localized to a small, asymmetrically located organ,
especially if another structure overlaps or obscures that organ.
Monkeys as Human Surrogate
Biodistribution of [11C](R)-rolipram in monkeys poorly estimated human radiation doses to
individual source organs and overestimated effective dose by 40%. As in humans, initial uptake
of activity was highest in monkey liver with a peak value of 24% injected activity shortly after
injection. However, hepatobiliary excretion of radioligand was not evident in monkeys, as the
gallbladder was not identifiable. Urinary excretion was far more predominant in monkeys.
Peak uptake of activity as a percentage of injected activity in kidneys and urinary bladder was
7% and 41%, respectively in monkeys. In humans, these values were 4% for the kidneys and
16% for the urinary bladder. As a result of these differences in excretion of radioligand, human
radiation doses to the gallbladder were underestimated by a factor of 0.15 in monkeys, and
doses to kidneys and urinary bladder wall were overestimated by factors of 2.89 and 1.36,
respectively.
Our results question the utility of performing whole body imaging in monkeys before studying
humans. Individual organs of monkeys can be inappropriate models for humans. In addition,
the overall measure of exposure, effective dose, can be significantly incorrect but still within
the range of values reported for other radioligands. Despite differences in the effective dose of
[11C](R)-rolipram estimated in monkeys (6.6 µGy/MBq) compared to humans (4.8 µGy/MBq),
both values are within the range of those for radioligands used in brain imaging. We recently
showed that the average effective dose for 12 other 11C-labeled tracers is 6.5 ± 2.6 µGy/MBq
(range, 4.3 – 14.1 µGy/MBq), with all results based on biodistribution data in humans [24]. In
light of the limited agreement of monkey and human dosimetry estimates, one could safely
assume that the human effective dose of a given 11C-labeled radioligand will be less than 14.1
µGy/MBq and then calculate an initial starting dose for human studies. The experimenter would
determine the actual effective dose from whole body imaging in humans and thereby obviate
any inaccuracies of the monkey as a human surrogate.
CONCLUSION
Whole-body PET demonstrated a modest radiation risk profile for the PDE4 imaging agent
[11C](R)-rolipram with an effective dose of 4.8 µGy/MBq. Human 2D planar images provided
slightly more conservative (i.e., higher) radiation dose estimates than did bisected and
quadrasected methods. Thus, the simpler and less time consuming 2D planar method appears
acceptable to estimate radiation burden for radioligands that are fairly broadly distributed in
the body (i.e., not concentrated in organs of high radiation sensitivity). In the event that small,
asymmetrically localized organs exhibit high levels of radioactivity, a combination of 2D
planar and bisected or quadrasected methods could be used to estimate more accurate radiation
doses to individual organs. The distribution of radioactivity to organs of the monkey was
different than that in humans and caused a 40% overestimation of the human effective dose.
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Figure 1.
Series of compressed whole-body 2D planar PET images for one healthy male. Images were
obtained about 0 – 2, 21 – 28, and 87 – 116 min after intravenous injection of 774 MBq [11C]
(R)-rolipram. All three decay-corrected images used the same gray scale (bottom of figure).
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Figure 2.
Mean decay-corrected activity in visually identifiable organs that have high (A) and low (B)
uptake after injection of [11C](R)-rolipram in 8 human subjects. Activities were determined
from 2D planar images.
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Figure 3.
Series of compressed whole-body 2D planar PET images for one male rhesus monkey. Images
were obtained about 1–2, 23–27, and 98–114 min after intravenous injection of 156 MBq
[11C](R)-rolipram. All three decay-corrected images used the same gray scale (bottom of
figure).
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Figure 4.
Mean decay-corrected activity in visually identifiable organs that have high (A) and low (B)
uptake after injection of [11C](R)-rolipram in two monkeys. A third monkey had similar time-
activity curves, but they could not be included in the average of those presented due to
differences in scan acquisition times. Activities were determined from 2D planar images.
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Figure 5.
Structure of (R)-rolipram showing the position of 11C used in PET imaging and 3H used in
clinical pharmacology studies.
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TABLE 1
Residence Times (h) of Identified Source Organs
Human* Monkey†
Organ 2D planar Bisected Quadrasected 2D planar
Brain 0.022 ± 0.004 0.021 ± 0.003 0.019 ± 0.003 0.035 ± 0.012
Gallbladder 0.008 ± 0.003 0.005 ± 0.002 0.004 ± 0.002 -
Heart 0.029 ± 0.003 0.023 ± 0.003 0.019 ± 0.003 0.007 ± 0.001
Kidneys 0.020 ± 0.006 0.013 ± 0.005 0.012 ± 0.005 0.028 + 0.003
Liver 0.083 ± 0.016 0.081 ± 0.016 0.079 ± 0.016 0.068 ± 0.021
Lungs 0.032 ± 0.002 0.034 ± 0.004 0.031 ± 0.004 0.040 ± 0.011
Urinary bladder 0.026 ± 0.007 0.025 ± 0.007 0.024 ± 0.007 0.082 ± 0.029
Remainder of body 0.259 ± 0.029 0.279 ± 0.027 0.293 ± 0.031 0.218 ± 0.067
*
Values are mean ± SD of 8 human subjects
†
Values are mean ± SD of 3 monkey subjects
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TABLE 2
Radiation Dose Estimates for [11C](R)-rolipram in Standard Reference Man
Human* Monkey†
2D planar Bisected Quadrasected 2D planar
Target Organ µGy/MBq Ratio to 2D planar Ratio to 2D planar Ratio to Human 2D
planar
Gallbladder wall 23.1 0.65 0.6 0.15
Kidneys 19.7 0.96 0.91 2.89
Urinary bladder wall 19.3 0.7 0.62 1.36
Liver 15.2 0.97 0.93 0.80
Heart wall 11.8 0.84 0.74 0.39
Lungs 9.6 1.03 0.94 1.15
Brain 5.2 0.97 0.91 1.60
Adrenals 3.4 0.97 0.97 0.88
Pancreas 3.3 0.98 0.98 0.84
Uterus 2.8 1.02 1.04 1.49
Osteogenic cells 2.8 1.05 1.08 0.90
Total body 2.7 1.01 1.01 0.96
Thymus 2.6 0.99 0.98 0.74
Upper large intestine wall 2.6 1.0 1.03 0.90
Stomach wall 2.5 1.01 1.03 0.85
Small intestine 2.5 1.02 1.05 0.96
Spleen 2.5 0.99 1.01 0.93
Ovaries 2.4 1.04 1.07 1.17
Lower large intestine wall 2.3 1.04 1.07 1.21
Muscles 2.1 1.03 1.06 0.95
Red marrow 2.0 1.02 1.03 0.94
Breasts 1.9 1.03 1.04 0.82
Thyroid 1.8 1.06 1.10 0.89
Testes 1.8 1.05 1.10 1.15
Skin 1.6 1.05 1.08 0.91
Effective dose equivalent 7.8 0.88 0.83 1.17
Effective dose 4.8 0.99 0.95 1.40
*
Values are mean of 8 human subjects
†
Values are mean of 3 monkey subjects
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